123
Views
5
CrossRef citations to date
0
Altmetric
Article Commentary

Toxicosurveillance of novel opioids: just screening tests may not be enough

ORCID Icon & ORCID Icon
Pages 271-272 | Received 11 Apr 2021, Accepted 12 Apr 2021, Published online: 19 May 2021

References

  • Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183–88. doi:10.1016/j.drugpo.2019.01.010.
  • Zoorob M. Fentanyl shock: the changing geography of overdose in the United States. Int J Drug Policy. 2019;70:40–46. doi:10.1016/j.drugpo.2019.04.010.
  • Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016. JAMA. 2018;319:1819–21. doi:10.1001/jama.2018.2844.
  • Salomone A, Di Corcia D, Negri P, Kolia M, Amante E, Gerace E, Vincenti M. Targeted and untargeted detection of fentanyl analogues and their metabolites in hair by means of UHPLC-QTOF-HRMS. Anal Bioanal Chem. 2021;413:225–33. doi:10.1007/s00216-020-02994-x.
  • Armenian P, Olson A, Anaya A, Kurtz A, Ruegner R, Gerona RR. Fentanyl and a novel synthetic opioid U-47700 masquerading as street “Norco” in Central California: a case report. Ann Emerg Med. 2017;69:87–90. doi:10.1016/j.annemergmed.2016.06.014.
  • Backberg M, Beck O, Jonsson KH, Helander A. Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. Clin Toxicol (Phila). 2015;53:609–17. doi:10.3109/15563650.2015.1054505.
  • Muller S, Nussbaumer S, Plitzko G, Ludwig R, Weinmann W, Krahenbuhl S, Liakoni E. Recreational use of carfentanil - a case report with laboratory confirmation. Clin Toxicol (Phila). 2018;56:151–52.
  • Palamar JJ, Salomone A, Bigiarini R, Vincenti M, Acosta P, Tofighi B. Testing hair for fentanyl exposure: a method to inform harm reduction behavior among individuals who use heroin. Am J Drug Alcohol Abuse. 2019;45:90–96. doi:10.1080/00952990.2018.1550652.
  • Barratt MJ, Latimer J, Jauncey M, Tay E, Nielsen S. Urine drug screening for early detection of unwitting use of fentanyl and its analogues among people who inject heroin in Sydney, Australia. Drug Alcohol Rev. 2018;37:847–50. doi:10.1111/dar.12864.
  • Mema SC, Sage C, Popoff S, Bridgeman J, Talyor D, Cornell D. Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia. Harm Reduct J. 2018;15:19. doi:10.1186/s12954-018-0224-z.
  • Goldman JE, Waye KM, Periera KA, Krieger MS, Yedinak JL, Marshall BDL. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. Harm Reduct J. 2019;16:3. doi:10.1186/s12954-018-0276-0.
  • Chhabra N, Rizvanolli L, Rasin A, Marsden G, Hinami K, Aks SE. A cross-sectional analysis of fentanyl analog exposures among living patients. Am J Drug Alcohol Abuse. 2021;1–6. doi:10.1080/00952990.2021.1891420.
  • Han Y, Yan W, Zheng Y, Khan MZ, Yuan K, Lu L. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Transl Psychiatry. 2019;11;9:282. doi:10.1038/s41398-019-0625-0.
  • Kenney SR, Anderson BJ, Conti MT, Bailey GL, Stein MD. Expected and actual fentanyl exposure among persons seeking opioid withdrawal management. J Subst Abuse Treat. 2018;86:65–69. doi:10.1016/j.jsat.2018.01.005.
  • Jones AA, Jang K, Panenka WJ, Barr AM, MacEwan GW, Thornton AE, Honer WG. Rapid change in fentanyl prevalence in a community-based, high-risk sample. JAMA Psychiatry. 2018;75:298–300. doi:10.1001/jamapsychiatry.2017.4432.
  • Salomone A, Palamar JJ, Bigiarini R, Gerace E, Di Corcia D, Vincenti M. Detection of fentanyl analogs and synthetic opioids in real hair samples. J Anal Toxicol. 2019;1;43:259–65. doi:10.1093/jat/bky093.
  • Green TC, Park JN, Gilbert M, McKenzie M, Struth E, Lucas R, Clarker W, Sherman SG. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy. 2020;77:102661. doi:10.1016/j.drugpo.2020.102661.
  • Salomone A, Palamar JJ, Vincenti M. Should NPS be included in workplace drug testing? Drug Test Anal. 2020;12:191–94. doi:10.1002/dta.2749.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.